What happened to allergy positions?

Quote
anonymous said:
They are giving them to the xolair reps basically. So good luck if you’re from any other division
Click to expand...
Xolair reps will have a challenge selling Remibrutinib, Xolair has better efficacy and safety. In addition, you should listen carefully during the Q3 report on October 29th. Will Remibrutinib be highlighted or even not be mentioned in a solely dedicated slide.
 












anonymous said:
Xolair reps will have a challenge selling Remibrutinib, Xolair has better efficacy and safety. In addition, you should listen carefully during the Q3 report on October 29th. Will Remibrutinib be highlighted or even not be mentioned in a solely dedicated slide.
Click to expand...
Ok, let’s all listen to the report and look specifically for ”one” solely dedicated slide for Remi....that’s hilarious. better yet, how about we all just wait for the approval next year and move forward from there. Btw, selling any product nowadays can be a challenge for a wide variety of reasons, but you sound really smart, so I’ll defer to your better judgement or do you think they should just cancel the Remi launch altogether? Seriously waiting on your response, I have an offer but I want to consider your advice before I decide.
 






























anonymous said:
I’m also in the the interview process. Any thoughts on how well this product and division are expected to do? I have a couple other options I’m looking into and just want to make the right call. Sounds like virtual training in December for new hires.
Click to expand...
Well, at least urticaria is now discussed in the media due to Kamala Harris's health record...
 














































































Top Bottom
Back
Quote